Viracta Therapeutics
Precision oncology company developing targeted therapies for virus-associated cancers, including EBV-positive lymphomas. Publicly traded on NASDAQ (VIRX).
Website
https://www.viracta.comLocation
San Diego, California, USA
Founded
2016
Investors
1
Categories
biotech, oncology, precision-medicine, virus-associated-cancer, public-company
Notes
Viracta Therapeutics is a precision oncology company developing targeted therapies for virus-associated cancers. The company is publicly traded on NASDAQ under the ticker symbol VIRX and is headquartered in San Diego, California.
The company focuses on cancers associated with viral infections, particularly Epstein-Barr virus (EBV). EBV is associated with several types of cancer, including:
- Certain lymphomas
- Nasopharyngeal carcinoma
- Gastric cancer
Viracta's approach leverages the unique biology of virus-associated cancers to develop targeted therapies that are more effective and less toxic than conventional chemotherapy.
Team
- Ivor Royston, M.D. - Founder & Executive Chairman
- Jeanne Mell - Chief Executive Officer
Additional Research Findings
- NASDAQ: VIRX (publicly traded)
- Portfolio company of aMoon
- Focus on virus-associated malignancies
- EBV-positive cancer programs
- San Diego, California headquarters
- Founded in 2016
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| aMoon | Tel Aviv, Israel | biotech-focused | series-aseries-b+2 | 8 |